- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Invikafusp Alfa Boasts High Disease Control Rate in Checkpoint Inhibitor–Resistant Solid Tumors
October 18th 2025, 6:55pm
Invikafusp alfa demonstrated early signals of antitumor activity across a range of biomarker-enriched patients with solid tumors.
Adjuvant Nivolumab Displays Long-Term Activity in Resected Melanoma
October 18th 2025, 6:40pm
Adjuvant nivolumab significantly extended RFS vs ipilimumab in patients with resected stage IIIB to IIIC or IV melanoma.
T-DXd Improves IDFS and DFS vs T-DM1 in HER2+ Breast Cancer With Residual Invasive Disease
October 18th 2025, 6:24pm
T-DXd significantly improved IDFS vs T-DM1 in high-risk, HER2-positive primary breast cancer with residual invasive disease after neoadjuvant therapy.
Incidence of Second Primary Tumors Is Similar Between Adjuvant Cemiplimab and Placebo in High-Risk CSCC
October 18th 2025, 6:10pm
Adjuvant cemiplimab and placebo were associated with similar rates of second primary tumors in high-risk CSCC.
Dr Chi on Potential Prognostic Markers for Lutetium Lu 177 Vipivotide Tetraxetan in PSMA+ mCRPC
October 18th 2025, 5:32pm
Kim Nguyen Chi, MD, FRCPC, discusses correlative analyses of prognostic subgroups in the phase 2 PR21 study in PSMA-positive mCRPC.
177-Lu-edotretide Prolongs PFS Compared With Everolimus in Grade 1/2 GEP-NETs
October 18th 2025, 5:19pm
177-Lu-edotretide significantly improved survival outcomes vs everolimus for the treatment of patients with grade 1/2 GEP-NETs.
Phase 2 BNT111/Cemiplimab Data Prove Positive in PD-(L)1-Relapsed/Refractory Melanoma
October 18th 2025, 4:22pm
BNT111 plus cemiplimab achieved an 18.1% ORR in PD-(L)1–refractory melanoma, meeting its primary end point in the phase 2 BNT111-01 trial.
Dr Sridhar on the Importance of Patient Selection for Benefit With Avelumab in PSCC
October 18th 2025, 3:53pm
Srikala Sridhar, MD, MSc, FRCPC, discusses efficacy findings from the ALPACA study and the necessity of improved patient selection for checkpoint inhibitors in PSCC
First-Line Tarlatamab/Chemoimmunotherapy Yields Early Efficacy Signals in ES-SCLC
October 18th 2025, 2:45pm
First-line treatment with tarlatamab plus chemoimmunotherapy and anti–PD-L1 maintenance therapy generated durable responses in patients with ES-SCLC.
Dato-DXd Plus Rilvegostomig Elicits Activity in Cisplatin-Ineligible or Platinum-Pretreated Urothelial Cancer
October 18th 2025, 1:46pm
Datopotamab deruxtecan plus rilvegostomig was active in cisplatin-ineligible and platinum-pretreated locally advanced or metastatic urothelial cancer.
Lenvatinib Plus Everolimus Yields PFS Benefit in Previously Treated Advanced Clear Cell RCC
October 18th 2025, 1:39pm
Lenvatinib plus everolimus improved PFS vs cabozantinib in metastatic clear cell renal cell carcinoma after progression on a PD-1 inhibitor.
Giredestrant/Everolimus Extends PFS for ER+, HER2– Advanced Breast Cancer
October 18th 2025, 1:14pm
Giredestrant plus everolimus improved progression-free survival in ER-positive, HER2-negative advanced breast cancer after a prior CDK4/6 inhibitor.
Belzutifan Plus Pembrolizumab and Lenvatinib Demonstrates Potential in Advanced Clear Cell RCC
October 18th 2025, 12:55pm
Belzutifan plus pembrolizumab and lenvatinib improved efficacy outcomes compared with multiple other pembrolizumab-based triplet regimens in advanced clear cell renal cell carcinoma.
RNA Sequencing Signatures May Guide Treatment Selection in Advanced ccRCC
October 18th 2025, 11:33am
RNAseq-defined clusters guided treatment selection in metastatic ccRCC in the phase 2 OPTIC trial, yielding a 76% ORR with cabozantinib plus nivolumab.
Fruquintinib Plus Sintilimab Improves PFS in Advanced RCC After First-Line VEGFR TKI Therapy
October 18th 2025, 1:59am
Fruquintinib plus sintilimab significantly extended progression-free survival in advanced RCC following first-line VEGFR TKI therapy.
Long-Term MANEUVER Trial Data Spotlight Durable Responses With Pimicotinib in TGCT
October 17th 2025, 11:20pm
Long-term data demonstrated durable responses with pimicotinib in tenosynovial giant cell tumor.
Regorafenib Plus Nivolumab Yields Nonsuperior Survival in Refractory Gastric/GEJ Cancer
October 17th 2025, 9:21pm
regorafenib/nivolumab may encourage a search for more non-chemotherapy combinations for gastric cancer.
Osimertinib Plus Chemo Demonstrates OS Benefit in EGFR+ NSCLC With Poor Prognostic Factors
October 17th 2025, 8:40pm
Osimertinib plus chemotherapy improved OS vs osimertinib alone in EGFR-mutated advanced non–small lung cancer, irrespective of poor prognostic factors.
SunRISe-4 Data Support Role for Neoadjuvant Gemcitabine Intravesical System Plus Cetrelimab in MIBC
October 17th 2025, 8:33pm
SunRISe-4 data show that TAR-200 and cetrelimab led to a high pCR and 12-month RFS rate in muscle-invasive bladder cancer.
Osimertinib Plus Local Consolidative Therapy Significantly Extends PFS in EGFR-Mutant NSCLC
October 17th 2025, 8:08pm
NorthStar findings support osimertinib plus local consolidative therapy in EGFR-mutant non–small cell lung cancer.